Clinical Trials List
2020-12-15 - 2029-12-31
Phase III
Recruiting10
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
-
Trial Applicant
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/14
Investigators and Locations
Co-Principal Investigator
- Huey-En Tzeng Division of Hematology & Oncology
- Wen-Ke Wang Division of General Surgery
- Shih Hsin Tu Division of Hematology & Oncology
- Kuan-Der Lee Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Chung Wu Division of General Surgery
- Chih-Jung Chen Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- 黃至豪 Division of General Surgery
- Chen-Teng Wu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Yu Hsieh Division of Hematology & Oncology
- KUAN-RAU CHIOU Division of Cardiovascular Diseases
- Tsu-Yi Chao Division of Hematology & Oncology
- I-Chan Lin Division of Ophthalmology
- HUI-WEN LIU Division of Hematology & Oncology
- Wei-Hong Cheng Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tai-Jan Chiu Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
- Yu-Li Su Division of Hematology & Oncology
- 李易濰 Division of Radiology
- 陳彥豪 Division of Hematology & Oncology
- 賴香蘭 Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- 陳彥仰 Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 陳怡豪 Division of Ophthalmology
- 劉文浩 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
- 周旭桓 Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
- 何蕙余 Division of General Surgery
- Wen-Chi Shen Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
- 沈士哲 Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
- Pei-Wei Huang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王國鐘 Division of General Surgery
- 林慈恩 Division of General Surgery
- 劉明承 Division of Radiology
- HSIN-CHEN LIN Division of Hematology & Oncology
- 楊陽生 Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- Huey-En Tzeng Division of Hematology & Oncology
- Kuan-Der Lee Division of Hematology & Oncology
- I-Chen Tsai Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Lung Kuo Division of General Surgery
- Zhu-Jun Loh Division of General Surgery
- Kuo-Ting Lee Division of General Surgery
- Chun-Hui Lee Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林柏翰 Division of General Internal Medicine
- 林季宏 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- MING-YANG WANG Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- 羅喬 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 魏以宣 Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
65 participants
-
Global
1680 participants
